Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA

Key Points

• Atlas Venture Life Science Advisors acquired 5.17 million Kailera Therapeutics shares worth approximately $113.9 million, making KLRA its fourth-largest holding and representing about 3.99% of the company. Wellington Management also established a new $64.3 million stake.
• Analyst sentiment is largely positive, with a consensus rating of “Moderate Buy” and an average price target of $42.75; individual targets range from $30 to $48, despite one recent downgrade to “sell.”
• Kailera shares opened at $15.74, near the lower end of their 52-week range, while the company reported a quarterly loss of $1.09 per share—worse than the $0.74 expected—and analysts forecast a full-year loss of $3.89 per share.

Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,171,282 shares of the company's stock, valued at approximately $113,923,000. Kailera Therapeutics comprises 12.9% of Atlas Venture Life Science Advisors LLC's holdings, making the stock its 4th largest position. Atlas Venture Life Science Advisors LLC owned about 3.99% of Kailera Therapeutics at the end of the most recent quarter.

Separately, Wellington Management Group LLP acquired a new stake in Kailera Therapeutics in the second quarter valued at $64,308,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on KLRA shares. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $48.00 target price for the company. Evercore assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an "outperform" rating on the stock. Leerink Partners assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an "overweight" rating and a $30.00 price objective for the company. Finally, Wall Street Zen downgraded Kailera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kailera Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $15.74 on Friday. The company has a market cap of $2.04 billion and a PE ratio of -0.00. Kailera Therapeutics, Inc. has a twelve month low of $15.15 and a twelve month high of $28.23. The firm has a 50-day moving average of $18.63.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, equities analysts forecast that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source